A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis

Sponsor
AbbVie
Study ID
NCT01148225
Phase
PHASE3
Status
Completed

Conditions

  • Uveitis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • adalimumab — DRUG
    Adalimumab, pre-filled syringe, administered by SC injection

Study Details

The purpose of this study is to evaluate the long term efficacy and safety of adalimumab participants with non-infectious intermediate-, posterior- or pan-uveitis.

Key Dates

Start date
Nov 23, 2010
Status verified
Jul 2021
Primary completion
May 21, 2018
Completion
May 21, 2018

Study Design

Enrollment
424 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Adalimumab
    Participants received open label (OL) adalimumab 40 mg by subcutaneous (SC) injection every other week (eow) until the final visit.

Primary Outcome Measure

Number of Participants With Adverse Events [ Time Frame: Baseline to Final Visit (up to 366 weeks) ]

Related Studies